MedTrace Logo

Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis

NCT00037102 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2018-04-12

No results posted yet for this study

Summary

The participant will receive weekly intramuscular treatment with AVONEX® (interferon beta 1-a) and bi-monthly high dose intravenous methotrexate with Leucovorin rescue.

Conditions

Interventions

DRUG

interferon beta 1a

DRUG

methotrexate

Sponsors & Collaborators

  • Consultants in Neurology

    collaborator INDUSTRY

  • Biogen

    collaborator INDUSTRY

  • MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute

    lead OTHER

Principal Investigators

  • Vernon D ROWE, MD · MidAmerica Research Foundation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-07-31
Primary Completion
2003-12-31
Completion
2003-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00037102 on ClinicalTrials.gov